Trial reportJournal of lipid research2016
Reduction in lipoprotein-associated apoC-III levels following volanesorsen therapy: phase 2 randomized trial results.
Trial report in Journal of lipid research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 101 citations in OpenAlex.
- N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels.European heart journal · 2019Trial
- A narrative review of impacts of apolipoproteins on atherosclerotic coronary plaques.NPJ cardiovascular health · 2026Review
- Targeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging Therapies.Current cardiology reports · 2026Review
- Advances in Non-statin Lipid Therapies: A Narrative Review of Evolving Strategies for Cardiovascular Risk Reduction.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2026Review
- Anti-apoC-III Therapies and Implications for Treatment of Pancreatitis and Cardiovascular Disease.Current atherosclerosis reports · 2025Review
- Novel Therapeutics for Familial Chylomicronemia Syndrome.Current atherosclerosis reports · 2025Review
- Comprehensive Review of Lipid Management in Chronic Kidney Disease and Hemodialysis Patients: Conventional Approaches, and Challenges for Cardiovascular Risk Reduction.Journal of clinical medicine · 2025Review
- Comparative Analysis of Plasma Lipids and Apolipoproteins in Children with Down Syndrome and Implications for Cardiovascular Risk.Archives of basic and applied medicine · 2024Article
- Article
- The Essence of Lipoproteins in Cardiovascular Health and Diseases Treated by Photodynamic Therapy.Biomedicines · 2024Review
- Exploring apolipoprotein C-III: pathophysiological and pharmacological relevance.Cardiovascular research · 2024Review
- Association between apolipoprotein C-III levels and coronary calcification detected by intravascular ultrasound in patients who underwent percutaneous coronary intervention.Frontiers in cardiovascular medicine · 2024Article
- Non-coding RNA therapeutics in cardiovascular diseases and risk factors: Systematic review.Non-coding RNA research · 2023Review
- Inflammation and atherosclerosis: signaling pathways and therapeutic intervention.Signal transduction and targeted therapy · 2022Review
- Early Investigational and Experimental Therapeutics for the Treatment of Hypertriglyceridemia.Journal of cardiovascular development and disease · 2022Review
- Hypertriglyceridemia may contribute to stroke and pancreatitis: A case report and review of the literature.Frontiers in endocrinology · 2022Review
- Lipid-Lowering Biotechnological Drugs: from Monoclonal Antibodies to Antisense Therapies-a Clinical Perspective.Cardiovascular drugs and therapy · 2021Review
- ANGPTL3 and Apolipoprotein C-III as Novel Lipid-Lowering Targets.Current atherosclerosis reports · 2021Review
- Opportunities and challenges for antisense oligonucleotide therapies.Journal of inherited metabolic disease · 2021Review
- Modified Oligonucleotides: New Structures, New Properties, and New Spheres of Application.Russian journal of bioorganic chemistry · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 2 countries.
Funding
Abstract
Elevated apoC-III levels predict increased cardiovascular risk when present on LDL and HDL particles. We developed novel high-throughput chemiluminescent ELISAs that capture apoB, lipoprotein (a) [Lp(a)], and apoA-I in plasma and then detect apoC-III on these individual lipoproteins as apoCIII-apoB, apoCIII-Lp(a), and apoCIII-apoAI complexes, respectively. We assessed the effects on these complexes of placebo or 100-300 mg volanesorsen, a generation 2.0+ antisense drug that targets apoC3 mRNA in patients with hypertriglyceridemia, including familial chylomicronemia syndrome (n = 3), volanesorsen monotherapy (n = 51), and as add-on to fibrate (n = 26), treated for 85 days and followed for 176 days. Compared with placebo, volanesorsen was associated with an 82.3 ± 11.7%, 81.3 ± 15.7%, and 80.8 ± 13.6% reduction in apoCIII-apoB, apoCIII-Lp(a), and apoCIII-apoA-I, respectively (300 mg dose;P< 0.001 for all), at day 92. Strong correlations in all assay measures were noted with total plasma apoC-III, chylomicron-apoC-III, and VLDL-apoC-III. In conclusion, novel high-throughput ELISAs were developed to detect lipoprotein-associated apoC-III, including for the first time on Lp(a). Volanesorsen uniformly lowers apoC-III on apoB-100, Lp(a), and apoA-I lipoproteins, and may be a potent agent to reduce triglycerides and cardiovascular risk mediated by apoC-III.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.